The themes Avita Medical is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
Built from Avita Medical, Inc.’s own filings with the U.S. Securities and Exchange Commission (SEC). Figures are as reported, with per-share history restated onto today’s share basis. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.
$15.60-3.3%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 5, 2026
Company outlook: revenue of $24.9M to $26.9M for Fiscal Q4 2026 — up 47.0% on a year earlier
Just reported
From Avita Medical's results release of November 5, 2026; its quarterly report has since been filed.
Actual
$26.1M
+53% y/y
+20% q/q
Guided
—
No guide given
Actual
-$0.20
Guided
—
No guide given
Actual
-$2.6M
Guided
—
No guide given
Q4 2026
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
Grade B
The band under the price shows the grade on each date, built only from filings that were public by then.
Showing 2 of 27 quarters of Avita Medical, Inc.’s grade history. The other 25 go back to November 2019.